• Customer Care
  • (888) 123-4567

Promoting Human Health
and Well Being

Read more

Our Science
Innovation

Merging our understanding of immune therapy with cutting-edge discoveries of how the microbiome functions, Rise is developing targeted immunotherapy drugs to treat a broad range of clinical indications.
Immunology

Immunology

We design immunological-based drugs to treat chronic diseases including autoimmunity, cancer, and infection.

Read more
Microbiome

Microbiome

Our understanding of microbiome science drives novel target identification and innovative drug design.

Read more
Synthetic Biology

Synthetic Biology

We use our proprietary oral biologics delivery technology to engineer novel immunological-directed cellular products.

Read more

Our Capabilities

PLATFORM

Synthetic Biology Medicine

As a foundational technology, Rise Therapeutics has developed the innovative and proprietary Tripartite X (TPX) drug delivery platform that embraces synthetic biology-based approaches to enable oral delivery of targeted biologic therapy.

Read more

INFRASTRUCTURE

Clinical
GMP
Manufacturing

Our clinical GMP drug production capabilities for microbial-based products including Live Biotherapeutic Products (LBPs) enables rapid and efficient translation of innovative bench discoveries towards commercialization.

Read more

Our Pipeline

At Rise Therapeutics, our product development focus, in-house clinical GMP manufacturing capabilities, and drug development experience enables us to pursue rapid and efficient novel drug development from innovative laboratory discoveries.
Image

Our Team

Gary Fanger, PHDFounder, President & CEO
Gary Fanger, PHD
Christian Furlan Freguia, PhD Senior VP of Research
Christian Furlan Freguia, PhD
Sathya Janardhanan, MS VP of Manufacturing
Sathya Janardhanan, MS
JANET STEPHENS, PhDSenior VP of Operations
JANET STEPHENS, PhD

Interested in working with Us?

Become a Partner

Rise Therapeutics is interested in evolving key partnerships with leading academic, biotechnology, and pharmaceutical groups that share our interest and commitment to develop innovative new medicines.

Read more

Join Our Team

We are always looking for extraordinary people with exceptional creativity and enthusiasm. In our collaborative, high performing, and entrepreneurial environment, we work as a team to investigate life saving products and treatments.

Read more

Our News

Rockville, Maryland, January 13, 2025 – Rise Therapeutics, a biotechnology company engaged in developing novel oral Immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a cancer Phase 1 clinical trial for its program candidate, R-5780. This is Rise Therapeutics’ fourth clinical program to enter patient clinical testing. For separate products, other clinical studies are ongoing for the treatment of ulcerative colitis, rheumatoid arthritis, and type 1 diabetes.

Rockville, Maryland, January 6th, 2025 – Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, today announced that it has completed dose escalation enrollment stages for both its R-2487 and R-3750 clinical trials. Both studies will now initiate the planned dose expansion stages to enroll additional patients at fixed doses.

Rockville, Maryland, October 22nd, 2024- Rise Therapeutics announced today that it has received funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institute of Health (NIH) to enable infrastructure improvement that will scale GMP production and accelerate quality assurance (QA) and quality control (QC), significantly enhancing its biologics drug manufacturing capabilities. This Commercial Readiness Pilot (CRP) Program SBIR award will also support Phase 2 clinical GMP manufacturing to advance Rise Therapeutics’ R-3750 program currently completing a Phase 1 proof-of-concept clinical trial in patients suffering from ulcerative colitis.